Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice[S]

Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice[S]

The transcription factors hepatic nuclear factor (HNF)1α and HNF1β can bind to the HNF1 site on the proprotein convertase subtilisin/kexin type 9 (PCSK9) promoter to activate transcription in HepG2 cells. However, it is unknown whether one or both HNF1 factors are obligatory for transactivating hepa...

Full description

Bibliographic Details
Main Authors:	Vikram Ravindra Shende, Minhao Wu, Amar Bahadur Singh, Bin Dong, Chin Fung Kelvin Kan, Jingwen Liu
Format:	Article
Language:	English
Published:	Elsevier 2015-04-01
Series:	Journal of Lipid Research
Subjects:	hepatic nuclear factor 1α hepatic nuclear factor 1β proprotein convertase subtilisin/kexin type 9 low density lipoprotein receptor low density lipoprotein cholesterol
Online Access:	http://www.sciencedirect.com/science/article/pii/S0022227520355620

Similar Items

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]
by: Frederick J. Raal, et al.
Published: (2016-06-01)

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
by: Øystein L. Holla, et al.
Published: (2011-10-01)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
by: Payal Kohli, et al.
Published: (2016-05-01)

Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE<sup>−/−</sup> Mice
by: Lili Gu, et al.
Published: (2019-11-01)

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
by: Yi Luo, et al.
Published: (2009-08-01)

PCSK9 Biology and Its Role in Atherothrombosis
by: Cristina Barale, et al.
Published: (2021-05-01)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
by: Dennis T. Ko, et al.
Published: (2018-11-01)

Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a
by: Chuan-Jue Cui, et al.
Published: (2020-05-01)

Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population
by: Ilaria Guella, et al.
Published: (2010-11-01)

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]
by: Brandon Ason, et al.
Published: (2014-11-01)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
by: Sarah J. Duellman, et al.
Published: (2017-08-01)

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
by: R. Huijgen, et al.
Published: (2012-05-01)

The PCSK9 decade
by: Gilles Lambert, et al.
Published: (2012-12-01)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
by: Michael D. Shapiro, et al.
Published: (2019-02-01)

Effects of Serum Estradiol on Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Lipid Profiles in Women Undergoing In Vitro Fertilization
by: Anna Papanikolaou, et al.
Published: (2024-01-01)

Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy
by: Jonathan Grimm, et al.
Published: (2021-04-01)

Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody[S]
by: Krista M. Schroeder, et al.
Published: (2015-11-01)

Familial Hypercholesterolemia
by: FENG Siqin, et al.
Published: (2023-01-01)

In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction
by: Bowen Lou, et al.
Published: (2022-10-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
by: Huang CC, et al.
Published: (2019-10-01)

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
by: Mali Liu, et al.
Published: (2010-09-01)

PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults
by: Matthew T. Mefford, et al.
Published: (2019-11-01)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
by: Niki Katsiki, et al.
Published: (2023-04-01)

Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies
by: Arrigo F.G. Cicero, et al.
Published: (2022-01-01)

THE INVOLVEMENT PROPROTEIN CONVERTASE SUBTILISIN/KEXIN OF TYPE 9 IN THE PATHOGENESIS OF ATHEROSCLEROSIS (LITERATURE REVIEW)
by: A. M. Chaulin
Published: (2020-03-01)

Computational Study of PCSK9-EGFA Complex with Effective Polarizable Bond Force Field
by: Jian Chen, et al.
Published: (2018-01-01)

Novel Low-Density Lipoprotein Cholesterol Reduction Therapies for the Secondary Prevention of Cardiovascular Disease
by: Xing Wang, et al.
Published: (2023-10-01)

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
by: Erik Stroes, et al.
Published: (2016-09-01)

Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008–2019
by: Levintow SN, et al.
Published: (2022-06-01)

A reassessment of the Japanese clinical diagnostic criteria of familial hypercholesterolemia in a hospital-based cohort using comprehensive genetic analysis
by: Hayato Tada, et al.
Published: (2020-11-01)

High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression
by: Coen van Solingen, et al.
Published: (2021-07-01)

Treatment of Hyperlipidemia: Consensus and Controversies
by: Christoph H Saely, et al.
Published: (2017-01-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i
by: Erin S. Mackinnon, et al.
Published: (2023-01-01)

Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials
by: Antonio J. Vallejo‐Vaz, et al.
Published: (2018-09-01)

Application of evolocumab in patients with coronary heart disease complicated with mild renal insufficiency
by: Zhang Yu, Wu Bin, Feng Jiaxu, Wang Rutao, Yuan Ming
Published: (2023-10-01)

Association of Lowering Low‐Density Lipoprotein Cholesterol With Contemporary Lipid‐Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta‐Analysis
by: Safi U. Khan, et al.
Published: (2019-04-01)

Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts
by: Shamanna S Iyengar
Published: (2016-01-01)

Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study
by: Massimiliano Ruscica, et al.
Published: (2017-05-01)